Under 21st Century Cures Legislation, Stem Cell Advocates Expect Regulatory Shortcuts
December 13, 2016
(Science) – As the 21st Century Cures Act cleared the U.S. Senate last week, many attendees of the annual World Stem Cell Summit (WSCS) here took a victory lap. The meeting assembled some of the lawyers, analysts, and activists who have long pushed for reform of how the U.S. Food and Drug Administration (FDA) handles regenerative medicine. And the behemoth biomedical bill predicted to get a presidential signature this week could allow some stem cell products a faster and more flexible premarket approval process.